Guidance

Inactivated influenza vaccine (Intanza®): patient group direction (PGD) template

PGD template to support the administration of intradermal inactivated influenza (Intanza®) vaccine in accordance with the national seasonal influenza vaccination programme.

From:
Public Health England
Published
24 September 2015
Last updated
24 July 2017 — See all updates

This publication was withdrawn on

Intradermal inactivated influenza vaccine (Intanza®) will not be manufactured for the 2017 to 2018 influenza season. See Influenza vaccine and intramuscular inactivated influenza vaccine PGD template for alternative vaccination.

Documents

Inactivated influenza vaccine (Intanza®): patient group direction (PGD) template

Ref: PHE publications gateway number 2015326

MS Word Document, 153 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This PGD template supports the administration of intradermal inactivated influenza vaccine (Intanza®) as part of the national seasonal influenza vaccination programme.

It is valid from 1 September 2017 to 31 March 2018.

Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012). Practitioners should follow local policy or procedures to access authorised PGD documents.

This PGD template should be used with reference to current national guidance, the Green Book, and Summary of Product Characteristics for the vaccine.

Published 24 September 2015
Last updated 24 July 2017 + show all updates

  1. Updated PGD template for the 2017 to 2018 influenza season.

  2. Updated patient group direction template valid up to 31 March 2017.

  3. First published.

Related content